{"Clinical Trial ID": "NCT01427933", "Intervention": ["INTERVENTION 1:", "Ramucirumab and Eribulina", "Ramucirumab (IMC-1121B) 10 mg/kg administered by intravenous infusion (IV) on day 1 of each 3-week cycle", "Uribulin 1.4 mg/m2 administered by bolus IV on day 1 and day 8 of each 3-week cycle", "INTERVENTION 2:", "Eribulin monotherapy", "Uribulin 1.4 mg/m2 administered by bolus IV on day 1 and day 8 of each 3-week cycle"], "Eligibility": ["Incorporation criteria:", "Have histologically or cytologically confirmed invasive breast cancer which, at the time of entry into the study, is either a local recurrent disease not suitable for curative treatment or stage IV disease (American Joint Committee on Cancer Staging Criteria for Breast Cancer)", "A measurable and/or non-measurable disease by response Assessment criteria for solid tumours version 1.1 (RECIST v1.1)", "Have received at least 2 but not more than 4 prior cytotoxic chemotherapys in the local recidivant or metastatic setting", "Have received prior treatment with anthracyclines and taxanes, either in a metastatic, adjuvant or neoadjuvant setting", "Have been treated with human epidermal growth factor (HER-2) receptor 2; or are not candidates for HER-2-directed therapy if the patient has a HER-2 positive disease", "After radiotherapy and/or hormonal treatment at least one week prior to randomization, he recovered from all clinically significant treatment-related toxicities.", "Have an Eastern Cooperative Oncology Group (ECOG) Yield status of 0 or 1", "Have left a ventricular ejection fraction within normal limits", "After stopping all previous chemotherapy treatments for cancer at least 3 weeks prior to randomization, he recovered clinically significant toxic effects.", "Of which the resolution of all clinically significant toxicities of prior chemotherapy, surgery, radiotherapy or hormonal therapy, except peripheral neuropathy, to class 1 or less [by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 4.0]], which must have been resolved to class 2 or less", "Have adequate haematological, hepatic, renal and coagulation function", "Negative pregnancy test", "Have a life expectancy of at least 3 months", "- Exclusion criteria:", "Have concomitant action other than adequate treatment of non-melanomatous skin cancer or other non-invasive or in situ neoplasms", "Are currently enrolled in a clinical trial for an experimental product, or are recently discontinued, or are enrolled simultaneously in any other type of medical research deemed not compatible with the study.", "Have received experimental treatment within 3 weeks prior to randomization", "Have already received ramucirumab or eribulin", "To have a known sensitivity to agents of similar biological composition such as ramucirumab, halichondrin B and/or the chemical derivative of halichondrin B", "Have received bevacizumab within 6 weeks prior to randomization", "Have uncontrolled or poorly controlled hypertension", "Have congenital prolonged QTc syndrome (or have a family history) or prolong the QTc interval at baseline", "Have a history of additional risk factors for point twists in the last year prior to randomization", "Have an implantable pacemaker or automatic implantable cardioverter defibrillator", "- Have a bradycardia.", "Have acute or subacute intestinal obstruction or a history of chronic diarrhoea requiring continuous medical intervention within 6 months prior to randomisation", "History of uncontrolled hereditary disorders or acquired haemorrhagic or thrombotic disorders", "Have had grade 3 or more bleeding in the 3 months prior to randomization", "You have experienced grade 3 or more arterial thromboembolic events in the 6 months prior to randomization, or venous thromboembolic events in the 3 months prior to randomization.", "After major surgery within 4 weeks prior to randomization or placement of a subcutaneous venous access device within 7 days prior to randomization", "A major surgical procedure is planned during the trial.", "Have uncontrolled metabolic conditions", "Have permanent or active infection requiring parenteral antibiotic, antifungal or antiviral treatment", "Have experienced human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)", "To have pulmonary lymphangitic disease that results in pulmonary dysfunction requiring active treatment, including the use of oxygen", "Have already received an allogeneic organ or tissue transplant", "A serious non-healing injury, ulcer or bone fracture were observed during the 4 weeks prior to randomization.", "Have known leptomeningal metastases", "Have cirrhosis (Child-Pugh Level B or worse) or cirrhosis (regardless of degree) and a history of clinically significant hepatic encephalopathy or ascites"], "Results": ["Performance measures:", "- Progression-free survival (PFS)", "The PFS was defined as the time from the date of randomization to the date of progression objectively determined by the criteria for assessing response in solid tumours (RECIST v1.1) or the death of a cause, depending on the first of these two causes. Progressive disease (PD) was defined as a 20% increase in the sum of the target injury with the sum showing an increase of 5 mm; the occurrence of a new injury or an unequivocal progression of non-target lesions.", "Time limit: Start of treatment until disease progression or death of any cause is documented up to 16.5 months", "Results 1:", "Title of the arm/group: Ramucirumab and Eribilin", "Ramucirumab (IMC-1121B) 10 mg/kg administered by intravenous infusion (IV) on day 1 of each 3-week cycle", "Uribulin 1.4 mg/m administered by bolus IV on day 1 and day 8 of each 3-week cycle", "Total number of participants analysed: 71", "Median (95% confidence interval)", "Unit of measure: month 4.4 (3.1 to 6.7)", "Results 2:", "Title of the arm/group: Eribilin monotherapy", "Description of the arm/group: Eribulin 1.4 mg/m administered by bolus IV on day 1 and day 8 of each 3-week cycle", "Total number of participants analysed: 70", "Median (95% confidence interval)", "Unit of measurement: month 4.1 (3.2 to 5.6)"], "Adverse Events": ["Undesirable Events 1:", "Total: 26/69 (37.68 per cent)", "Anemia 2/69 (2.90%)", "- Febrile neutropenia 3/69 (4.35 per cent)", "Neutropenia 4/69 (5.80%)", "Cardiac arrest 1/69 (1.45%)", "Congestive heart failure 1/69 (1.45%)", "- Cardiac Tapponade 1/69 (1.45%)", "1/69 (1.45%)", "Abdominal pain 1/69 (1.45%)", "Ascites 2/69 (2.90%)", "- Collision 1/69 (1.45%)", "Gastritis 1/69 (1.45%)", "Erosive gastritis 1/69 (1.45%)", "Adverse Events 2:", "Total: 12/65 (18.46 per cent)", "Anemia 0/65 (0.00 %)", "Febrile neutropenia 1/65 (1.54%)", "Neutropenia 1/65 (1.54%)", "Cardiac arrest 0/65 (0.00 %)", "- Congestive heart failure 0/65 (0.00 %)", "- Cardiac tamponade 0/65 (0.00 %)", "Pericardial infusion 0/65 (0.00 %)", "Abdominal pain 2/65 (3.08%)", "Ascites 2/65 (3.08%)", "- Collision 0/65 (0.00 %)", "Gastritis 0/65 (0.00 %)", "Erosive gastritis 0/65 (0.00 %)"]}